Balancing innovation with the rising costs of therapies and value-based payment models is top of mind this week at the largest annual gathering of oncologists.
French drug company Sanofi is trying to toss the entire board at Medivation after the U.S. drugmaker rejected its $9.3 billion takeover bid.
The Food and Drug Administration will take more time to review a highly contested drug for muscular dystrophy that has become a flashpoint in the debate over patient access to experimental medicine.
The trial of a former Warner Chilcott president may be among the first of more to come for healthcare executives as the Justice Department increasingly holds individuals accountable for corporate wrongdoing.
German drug and chemicals company Bayer announced Monday that it has made a $62 billion offer to buy U.S.-based crops and seeds specialist Monsanto.
While the latest cancer drugs emerging from drug and biotechnology company labs can come with hefty price tags, they don't necessarily have a lot of evidence showing they actually work.
For the third time, the FDA has delayed a rule requiring generic-drug companies to update product labels if they receive new safety information.
Colombia's government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of the medicine broken and competition thrown open to generic rivals.
U.S. regulators have approved the first drug for bladder cancer that harnesses the body's immune system. It is the first advance in decades against the most common type of bladder cancer, one which almost always kills patients within months.
Pfizer will acquire Anacor Pharmaceuticals in a deal valued at about $5.2 billion. Anacor's topical treatment for eczema, called crisaborole, is currently under review by the FDA. If approved, Pfizer said it believes peak year sales could reach or exceed $2 billion.
Vermont is poised to become the first state requiring drug companies to explain their price increases, and Bob and Deborah Messing think that's a good idea.
Oracle founder Larry Ellison has donated $200 million to the University of Southern California to fund a cancer research center, matching the largest single donation ever received by the school.